Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

Thursday August 13, 2009

PennyOmega.com Stock Report!

**************************************************************

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has filed a patent for a novel composition and method for oral delivery of cobra venom for the treatment of pain.

Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,650,000 shares of common stock. Gross proceeds from the offering of an aggregate of 12,650,000 shares at a price to the

Nutra Pharma Corp., a biotechnology company that develops treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced yesterday that its drug discovery subsidiary ReceptoPharm published the positive results of its recent pain study in Toxicon, the official journal of the International Society on Toxinology. The study examined RPI-78, ReceptoPharm’s leading drug candidate for the treatment of pain, revealing that its pain reducing effects lasted four-times as long as morphine, without its associated negative side effects.

“The results from this study provide a significant step forward in the development of an effective and non-narcotic treatment for moderate to severe pain,” commented Dr. Paul Reid, CEO of ReceptoPharm. “With these results in hand, we believe that RPI-78 could become the first non opioid-based analgesic dedicated to treating Stage II and Stage III pain,” he added.

The ReceptoPharm study revealed that RPI-78 has a dose-dependent inhibitory effect on the electrical activity of Pf neurons

Nutra Pharma Corp., a biotechnology company focused on developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has introduced a line of specialized contract research services targeted at the early-stage life science market.

“As a clinical stage company specializing in biologics, we understand and have cleared many of the hurdles that face emerging biotech companies,” stated Dr. Paul Reid, CEO of ReceptoPharm. “This knowledge, combined with our qualified drug production facility, allows us to leverage our expertise and capabilities by extending them to small and start-up biotechnology companies looking for cost effective outsourcing solutions for their clinical development projects.”

The services being introduced by ReceptoPharm include pre-production studies, contract manufacturing, United States and European Union regulatory support, and quality systems and GMP certification. The company can also prepare and sterile fill pharmaceutical products in its ISO class 5 cleanroom facilities